David C. Rubinsztein

David Rubinsztein
David Rubinsztein in 2014 at the University of Cambridge
Born David Chaim Rubinsztein
1963 (age 54–55)
Alma mater University of Cape Town (MBChB, PhD)
Known for autophagy and polyglutamine expansions
Awards
Scientific career
Fields Autophagy
Neurodegenerative diseases[4]
Institutions University of Cambridge
Cambridge Institute for Medical Research
Cambridge Drug Discovery Institute
Thesis Monogenic hypercholesterolemia in South Africans: familial hypercholesterolemia in Indians and familial defective apolipoprotein B-100 (1993)
Doctoral advisor Prof. D.R. van der Westhuyzen
Website

David Chaim Rubinsztein (born 1963) FRS[3] FMedSci[5] is the Deputy Director of the Cambridge Institute of Medical Research (CIMR),[6] the Academic Lead of the Alzheimer's Research UK (ARUK) Cambridge Drug Discovery Institute,[7], Professor of Molecular Neurogenetics at the University of Cambridge.[8] and a UK Dementia Research Institute Professor.

Education

Rubinsztein completed his Bachelor of Medicine, Bachelor of Surgery (MB ChB) in 1986 and PhD in 1993 in the Medical Research Council/University of Cape Town Unit for the Cell Biology of Atherosclerosis. In 1993 he went to Cambridge as a senior registrar in Genetic Pathology.[9]

Career

In 1997, Rubinsztein acquired his Certificate of Completion of Specialist Training at the University of Cambridge. He was appointed to a Personal Readership at the University of Cambridge in 2003. In 2005, he was promoted to Professor of Molecular Neurogenetics at the University of Cambridge (personal chair). He has been an author on more than 300 scientific papers,[4][10] and was ranked as the 4th most cited European author from 2007 to 2013 in cell biology.[11] Rubinsztein has been invited to give talks at major international conferences, including Gordon Research Conferences and Keystone Symposia.[12][13][14]

Research

Rubinsztein has made major contributions to the field of neurodegeneration[4] with his laboratory's discovery that autophagy regulates the levels of intracytoplasmic aggregate-prone proteins that cause many neurodegenerative diseases, including Huntington's, Parkinson's and Alzheimer's disease.[15][16][17][18][19] His lab has found that autophagy may be inhibited in various neurodegenerative diseases[20] and has elucidated the pathological consequences of autophagy compromise.[21] In addition his research has advanced the basic understanding of autophagy, identifying the plasma membrane as a source of autophagosome membrane[22] and characterising early events in autophagosome biogenesis,.[23][24][25] Furthermore, he studied how lysosomal positioning regulates autophagy.[26] His goal is to understand the links between these diseases and autophagy. He is currently focused on understanding how to induce autophagy in vivo to remove toxic proteins and avoid the development of neurodegenerative disease[6][27]

Honours and awards

Rubinsztein has won numerous awards including:

References

  1. ↑ https://acmedsci.ac.uk/more/news/14-academy-fellows-elected-to-the-royal-society-in-2017
  2. 1 2 "EMBO people: David C. Rubinsztein". people.embo.org.
  3. 1 2 3 Anon (2017). "Professor David Rubinsztein FRS". London: royalsociety.org.
  4. 1 2 3 David C. Rubinsztein publications indexed by Google Scholar Edit this at Wikidata
  5. 1 2 Anon (2004). "Professor David Rubinsztein FMedSci". acmedsci.ac.uk. London: Academy of Medical Sciences.
  6. 1 2 "Professor David C. Rubinsztein". University of Cambridge.
  7. ↑ Cambridge Drug Discovery Institute Cambridge
  8. ↑ "Professor David Rubinsztein :: Cambridge Neuroscience". www.neuroscience.cam.ac.uk. Retrieved 2018-01-08.
  9. ↑ F1000 Prime Faculty Member
  10. ↑ Research Gate
  11. ↑ Publication analysis 2007–2013, Cell Biology
  12. ↑ "Centre for Science and Policy". University of Cambridge.
  13. ↑ Renna, M.; Jimenez-Sanchez, M.; Sarkar, S.; Rubinsztein, D. C. (2010). "Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases". Journal of Biological Chemistry. 285 (15): 11061–11067. doi:10.1074/jbc.R109.072181. ISSN 0021-9258. PMC 2856980.
  14. ↑ "Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases". .jbc.org.
  15. ↑ Rubinsztein, D. C. (2012). "Autophagy modulation as a potential therapeutic target for diverse diseases". Nature Reviews Drug Discovery. 11: 709–730. doi:10.1038/nrd3802. PMC 3518431.
  16. ↑ Ravikumar, B.; Rubinsztein, D. C. (2004). "Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease". Nature Genetics. 36: 585–595. doi:10.1038/ng1362. PMID 15146184.
  17. ↑ Analytics, Clarivate. "David Rubinsztein Interview - Special Topic of Autophagy - ScienceWatch.com". archive.sciencewatch.com. Retrieved 2018-01-08.
  18. ↑ Davies, J. E.; Rubinsztein, D. C. (2005). "Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice". Nature Medicine. 11: 672–677. doi:10.1038/nm1242. PMID 15864313.
  19. ↑ Sarkar, S.; Rubinsztein, D. C. (2007). "Small molecules enhance autophagy and reduce toxicity in Huntington's disease models". Nature Chemical Biology. 3: 331–338. doi:10.1038/nchembio883. PMC 2635561. PMID 17486044.
  20. ↑ Winslow, A. R.; Rubinsztein, D. C. (2010). "α-Synuclein impairs macroautophagy: implications for Parkinson's disease". The Journal of Cell Biology. 190 (6): 1023–1037. doi:10.1083/jcb.201003122. PMC 3101586.
  21. ↑ Ravikumar, B.; Rubinsztein, D. C. (2005). "Dynein mutations impair autophagic clearance of aggregate-prone proteins". Nature Genetics. 37: 771–776. doi:10.1038/ng1591. PMID 15980862.
  22. ↑ Ravikumar, B.; Rubinsztein, D. C. (2010). "Plasma membrane contributes to the formation of pre-autophagosomal structures". Nature Cell Biology. 12: 747–757. doi:10.1038/ncb2078. PMC 2923063. PMID 20639872.
  23. ↑ Moreau, K.; Rubinsztein, D. C. (2011). "Autophagosome precursor maturation requires homotypic fusion". Cell. 146: 303–317. doi:10.1016/j.cell.2011.06.023. PMC 3171170. PMID 21784250.
  24. ↑ Puri, C.; Rubinsztein, D. C. (2013). "Diverse autophagosome membrane sources coalesce in recycling endosomes". Cell. 154: 1285–1299. doi:10.1016/j.cell.2013.08.044. PMC 3791395. PMID 24034251.
  25. ↑ Vicinanza, M.; Rubinsztein, D. C. (2015). "PI(5)P regulates autophagosome biogenesis". Molecular Cell. 57: 219–234. doi:10.1016/j.molcel.2014.12.007.
  26. ↑ Korolchuk, V. I.; Rubinsztein, D. C. (2011). "Lysosomal positioning coordinates cellular nutrient responses". Nature Cell Biology. 13: 453–460. doi:10.1038/ncb2204.
  27. ↑ "Autophagy, a guardian against neurodegeneration - Part 2 - David Rubinsztein". SENS Research Foundation. 2013-11-27. Retrieved 2018-01-08.
  28. ↑ Wellcome Trust
  29. ↑ "Editor biographies". Nature.
  30. 1 2 Thomson Reuters
  31. ↑ http://www.labtimes.org/labtimes/ranking/2015_05/index.lasso
  32. ↑ "2017 Award Winners". biochemistry.org.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.